Cargando…
GLP-1 receptor agonists, SGLT-2 inhibitors, and obstructive sleep apnoea: can new allies face an old enemy?
Obstructive sleep apnoea (OSA) is the most common form of abnormal sleep pattern (ASP). It is characterized by narrowing of the upper airways (complete or partial) during sleep. Although continuous positive airway pressure is recognized as the gold standard treatment of OSA, unfortunately treatment...
Autor principal: | Papaetis, Georgios S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161791/ https://www.ncbi.nlm.nih.gov/pubmed/37153372 http://dx.doi.org/10.5114/amsad/161170 |
Ejemplares similares
-
Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
por: Khedagi, Apurva, et al.
Publicado: (2023) -
Obstructive sleep apnoea and cardiovascular disease: a literature review
por: Assallum, Hussein, et al.
Publicado: (2019) -
Impact of surgical maxillomandibular advancement upon pharyngeal airway volume and the apnoea–hypopnoea index in the treatment of obstructive sleep apnoea: systematic review and meta-analysis
por: Giralt-Hernando, Maria, et al.
Publicado: (2019) -
Empagliflozin therapy and insulin resistance-associated disorders: effects and promises beyond a diabetic state
por: Papaetis, Georgios S.
Publicado: (2021) -
Pioglitazone in diabetic kidney disease: forgotten but not gone
por: Papaetis, Georgios S.
Publicado: (2022)